FDA Arthritis Drug Advisory Committee
Executive Summary
Ciba-Geigy's Voltaren NDA is on the agenda for the panel's May 16-17 meeting. The panel will also review the status of revised guidelines for the clinical evaluation of NSAIDs. McNeil Labs will also report on a follow-up program on the long-term effects of Suprol. Merck's Clinoril is also on the agenda. The committee will meet in FDA's Parklawn conference rooms D & E 8:30 a.m. both days.